Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Cancer 4, 371–380 (1 May 2004) | doi:10.1038/nrc1365
Molecules and mechanisms of the graft-versus-leukaemia effect
&
Abstract
The ability of allogeneic bone-marrow cells and peripheral-blood stem cells to cure leukaemia remains the most striking example of the ability of the human immune system to recognize and destroy tumours. However, harnessing this 'graft-versus-leukaemia' effect to improve outcome for patients with advanced disease and segregating it from graft-versus-host disease have proven to be key challenges. The recent identification of molecules that are specifically expressed by leukaemic cells and that can be recognized by T cells has indicated that immunological reactivity can be targeted. This anticancer specificity of T cells should soon be routinely incorporated into allogeneic stem-cell transplant regimens to promote tumour eradication.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
